EU CHMP Adopts Positive Opinion Recommending Approval Of KEYTRUDA, Merck’s Anti-PD-1 Therapy, In Combination With Padcev As Neoadjuvant Treatment For Adults With Resectable Muscle-Invasive Bladder Cancer